Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.21 - $39.50
Previous CloseN/A
Volume154.73K
Average Volume (3M)477.49K
Market Cap
$564.42M
Enterprise Value$720.33M
Total Cash (Recent Filing)$265.71M
Total Debt (Recent Filing)$346.46M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 11, 2025EPS Estimate
-1.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding27,996,964
10 Day Avg. Volume519,604
30 Day Avg. Volume477,489
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue5.85
Enterprise Value/Gross Profit5.91
Enterprise Value/Ebitda-10.82
Forecast
1Y Price Target
$51.50Price Target Upside165.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsRosnilimab showed ACR20 responses of high 70% with more than 20% separation from placebo, indicating superior performance.
Drug DevelopmentManagement sounded positive on rosnilimab's chances in ulcerative colitis.
Financial PerformanceGSK announced strong commercial performance for Jemperli, with momentum suggesting it will exceed $1B in 2025 and generate a $75M milestone to ANAB.
Bears Say
Market CompetitionJNJ's drug appears flawed relative to rosnilimab, with discouraging results in ulcerative colitis trials.
Stock ValuationShares are trading at a large discount.
AnaptysBio News
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $39.50 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $564.42M.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Nov 11, 2025 which is in 54 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Aug 06, 2025. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.551 by $0.211.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -1.44.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 27,996,964 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.551. Following the earnings report the stock price went down -9.627%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.50 (165.46% Upside)
$51.50 (165.46% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 290.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 20.0%
Last 30 Days ▲ 20.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.01%
12-Months-Change
Fundamentals
Return on Equity
-343.83%
Trailing 12-Months
Asset Growth
-21.56%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$51.50
▲(165.46% Upside)
Technical Analysis
Ownership Overview
45.18% Insiders
15.02% Mutual Funds
0.18% Other Institutional Investors
30.15% Public Companies and
Individual Investors